• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates

by jtcir-auto | May 5, 2021 | Press Releases

– Q12021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets- Pivotal Phase 3DETECT(Study P02) safety and efficacy study evaluating macimorelin diagnostic for CGHD on track to...

Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates

by jtcir-auto | May 5, 2021 | Press Releases

– Q12021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets- Pivotal Phase 3DETECT(Study P02) safety and efficacy study evaluating macimorelin diagnostic for CGHD on track to...

Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer

by jtcir-auto | May 3, 2021 | Press Releases

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncologyCHARLESTON, S.C., May 03, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...

Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer

by jtcir-auto | May 3, 2021 | Press Releases

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncologyCHARLESTON, S.C., May 03, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...

Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders

by jtcir-auto | Apr 28, 2021 | Press Releases

CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow